594 related articles for article (PubMed ID: 23614352)
21. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.
Yap DB; Chu J; Berg T; Schapira M; Cheng SW; Moradian A; Morin RD; Mungall AJ; Meissner B; Boyle M; Marquez VE; Marra MA; Gascoyne RD; Humphries RK; Arrowsmith CH; Morin GB; Aparicio SA
Blood; 2011 Feb; 117(8):2451-9. PubMed ID: 21190999
[TBL] [Abstract][Full Text] [Related]
22. Polycomb Repressive Complex 2 Proteins EZH1 and EZH2 Regulate Timing of Postnatal Hepatocyte Maturation and Fibrosis by Repressing Genes With Euchromatic Promoters in Mice.
Grindheim JM; Nicetto D; Donahue G; Zaret KS
Gastroenterology; 2019 May; 156(6):1834-1848. PubMed ID: 30689973
[TBL] [Abstract][Full Text] [Related]
23. Distinct Stimulatory Mechanisms Regulate the Catalytic Activity of Polycomb Repressive Complex 2.
Lee CH; Holder M; Grau D; Saldaña-Meyer R; Yu JR; Ganai RA; Zhang J; Wang M; LeRoy G; Dobenecker MW; Reinberg D; Armache KJ
Mol Cell; 2018 May; 70(3):435-448.e5. PubMed ID: 29681498
[TBL] [Abstract][Full Text] [Related]
24. The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat.
Kuntz KW; Campbell JE; Keilhack H; Pollock RM; Knutson SK; Porter-Scott M; Richon VM; Sneeringer CJ; Wigle TJ; Allain CJ; Majer CR; Moyer MP; Copeland RA; Chesworth R
J Med Chem; 2016 Feb; 59(4):1556-64. PubMed ID: 26769278
[TBL] [Abstract][Full Text] [Related]
25. The role of EZH1 and EZH2 in development and cancer.
Lee SH; Li Y; Kim H; Eum S; Park K; Lee CH
BMB Rep; 2022 Dec; 55(12):595-601. PubMed ID: 36476271
[TBL] [Abstract][Full Text] [Related]
26. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.
Qi W; Chan H; Teng L; Li L; Chuai S; Zhang R; Zeng J; Li M; Fan H; Lin Y; Gu J; Ardayfio O; Zhang JH; Yan X; Fang J; Mi Y; Zhang M; Zhou T; Feng G; Chen Z; Li G; Yang T; Zhao K; Liu X; Yu Z; Lu CX; Atadja P; Li E
Proc Natl Acad Sci U S A; 2012 Dec; 109(52):21360-5. PubMed ID: 23236167
[TBL] [Abstract][Full Text] [Related]
27. Ezh1 and Ezh2 differentially regulate PSD-95 gene transcription in developing hippocampal neurons.
Henriquez B; Bustos FJ; Aguilar R; Becerra A; Simon F; Montecino M; van Zundert B
Mol Cell Neurosci; 2013 Nov; 57():130-43. PubMed ID: 23932971
[TBL] [Abstract][Full Text] [Related]
28. Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
Woo J; Kim HY; Byun BJ; Chae CH; Lee JY; Ryu SY; Park WK; Cho H; Choi G
Bioorg Med Chem Lett; 2014 Jun; 24(11):2486-92. PubMed ID: 24767850
[TBL] [Abstract][Full Text] [Related]
29. Regulation of Retinal Development via the Epigenetic Modification of Histone H3.
Watanabe S; Murakami A
Adv Exp Med Biol; 2016; 854():635-41. PubMed ID: 26427469
[TBL] [Abstract][Full Text] [Related]
30. Sex-biased genetic programs in liver metabolism and liver fibrosis are controlled by EZH1 and EZH2.
Lau-Corona D; Bae WK; Hennighausen L; Waxman DJ
PLoS Genet; 2020 May; 16(5):e1008796. PubMed ID: 32428001
[TBL] [Abstract][Full Text] [Related]
31. Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target.
Agarwal P; Alzrigat M; Párraga AA; Enroth S; Singh U; Ungerstedt J; Österborg A; Brown PJ; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
Oncotarget; 2016 Feb; 7(6):6809-23. PubMed ID: 26755663
[TBL] [Abstract][Full Text] [Related]
32. Long residence time inhibition of EZH2 in activated polycomb repressive complex 2.
Van Aller GS; Pappalardi MB; Ott HM; Diaz E; Brandt M; Schwartz BJ; Miller WH; Dhanak D; McCabe MT; Verma SK; Creasy CL; Tummino PJ; Kruger RG
ACS Chem Biol; 2014 Mar; 9(3):622-9. PubMed ID: 24304166
[TBL] [Abstract][Full Text] [Related]
33. [Effects of Histone Methyltransferase Inhibitors on the Survival, Apoptosis and Cell Cycle of Raji Cells].
Xiao LR; Hou C; Zheng SJ; Guo B; Chen DN; Yan NH
Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 May; 50(3):305-310. PubMed ID: 31631594
[TBL] [Abstract][Full Text] [Related]
34. H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in Ex Vivo Cultures of Resting CD4+ T Cells.
Tripathy MK; McManamy ME; Burch BD; Archin NM; Margolis DM
J Virol; 2015 Aug; 89(16):8392-405. PubMed ID: 26041287
[TBL] [Abstract][Full Text] [Related]
35. The competitive mechanism of EZH1 and EZH2 in promoting oral squamous cell carcinoma.
Chen J; Tang S; Zheng Q; Li J; Jiang H; Lu H; Liao G; Li K; Liang Y
Exp Cell Res; 2024 Mar; 436(1):113957. PubMed ID: 38309675
[TBL] [Abstract][Full Text] [Related]
36. Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myeloma.
Nakagawa M; Fujita S; Katsumoto T; Yamagata K; Ogawara Y; Hattori A; Kagiyama Y; Honma D; Araki K; Inoue T; Kato A; Inaki K; Wada C; Ono Y; Yamamoto M; Miura O; Nakashima Y; Kitabayashi I
Cancer Sci; 2019 Jan; 110(1):194-208. PubMed ID: 30343511
[TBL] [Abstract][Full Text] [Related]
37. Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
Xu B; Konze KD; Jin J; Wang GG
Exp Hematol; 2015 Aug; 43(8):698-712. PubMed ID: 26027790
[TBL] [Abstract][Full Text] [Related]
38. Inhibitors of the Histone Methyltransferases EZH2/1 Induce a Potent Antiviral State and Suppress Infection by Diverse Viral Pathogens.
Arbuckle JH; Gardina PJ; Gordon DN; Hickman HD; Yewdell JW; Pierson TC; Myers TG; Kristie TM
mBio; 2017 Aug; 8(4):. PubMed ID: 28811345
[TBL] [Abstract][Full Text] [Related]
39. Novel 3-methylindoline inhibitors of EZH2: Design, synthesis and SAR.
Ansari A; Satalkar S; Patil V; Shete AS; Kaur S; Gupta A; Singh S; Raja M; Severance DL; Bernales S; Chakravarty S; Hung DT; Pham SM; Herrera FJ; Rai R
Bioorg Med Chem Lett; 2017 Jan; 27(2):217-222. PubMed ID: 27923618
[TBL] [Abstract][Full Text] [Related]
40. Maternal Ezh1/2 deficiency in oocyte delays H3K27me2/3 restoration and impairs epiblast development responsible for embryonic sub-lethality in mouse.
Zhao Y; Bai D; Wu Y; Zhang D; Liu M; Tian Y; Lu J; Wang H; Gao S; Lu Z
Development; 2022 Aug; 149(15):. PubMed ID: 35796552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
